Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-03-08
2000-05-02
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514369, 514370, 548182, 548186, 548189, 548190, 548193, 548196, 548197, 548205, A61K 31425, C07D27710, C07D27728
Patent
active
06057349&
ABSTRACT:
The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--, --CH.sub.2 --, or --OCH.sub.2 --; Y is [2-imidazoline, 2-oxazolin] 2-thiazoline, [or 4-imidazole] R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.
REFERENCES:
patent: 2663732 (1953-12-01), Weissberger et al.
patent: 3340298 (1967-09-01), Wismayr et al.
patent: 4238497 (1980-12-01), Black et al.
patent: 4343808 (1982-08-01), Broersma, Jr. et al.
patent: 4414223 (1983-11-01), Copp et al.
patent: 4492709 (1985-01-01), Purcell
patent: 4665085 (1987-05-01), Coquelet et al.
patent: 4665095 (1987-05-01), Winn et al.
patent: 4956388 (1990-09-01), Robertson et al.
patent: 5360822 (1994-11-01), Morino et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5541210 (1996-07-01), Cupps et al.
patent: 5556753 (1996-09-01), Bard et al.
patent: 5578611 (1996-11-01), Gluchowski et al.
patent: 5578616 (1996-11-01), Aslanian et al.
patent: 5597823 (1997-01-01), Meyer et al.
patent: 5610174 (1997-03-01), Craig et al.
patent: 5716966 (1998-02-01), Cupps et al.
Gh. Botez et al., Chemical Abstract 6834 (1964) (Abstract Only).
Wein, Urologic Clinics of North America (1995) 22:557-577.
Lundberg (editor), JAMA (1989) 261 (18):2685-2690.
Anderson and Sjogren, Progress in Neurobiology (1982) 19:71-89).
Sourander, Gerontology (1990) 36:19-26.
Hieble, et al., Pharmacol. Revs. (1995) 47:267-270).
Schwinn, et al., J. Biol. Chem. (1990) 265:8183-8189).
Ford, et al., Trends Pharmacol. Sci. (1994) 15:167-170.
Flavahan and Vanhoutte, Trends Pharmacol. Sci. (1986) 7:347-349.
Muramatsu, et al., Br. J. Pharmacol. (1990) 99:197-201).
Ford, et al., Mol. Pharmacol. (1996) 49:209-215).
Ford, et al., Br. J. Pharmacol. (1997) 121:1127-1135.
Forray, et al., Mol. Pharmacol. (1994) 45:703-708.
Latifpour, et al., J.Pharmacol Exp. Ther. (1990) 253:661-667).
Tsujimoto, et al., J. Pharmacol. Exp. Ther. (1986) 236:384-389.
Yoshida, et al., J. Pharmacol. Exp. Ther. (1991) 257:1100-1108.
Chess-Williams, et al., J. Auton. Pharmacol. (1994) 14:375-381).
Proctor, Am. Rev. Resp. Dis. (1977) 115:97-129).
Proctor, et al., Pharmac. Ther. B. (1976) 2:493-509.
Scadding, Clin. Exp. Allergy (1995) 25:391-394.
Langer, Biochem. Pharmacol. (1974) 23:1793-1800).
Ichimura and Chow, Arch Otorhinolaryngol (1988) 245:127-131.
Anderson, et al., Ann. Otol. Rhinol. Laryngol. (1984) 93:179-182).
Ichimura and Jackson, Arch Otolaryngol (1984) 110;647-651.
Lung, et al., J. Physiol. (1984) 349:535-551.
Empey et al., Drugs (1981) 21:438-443.
Minneman, et al., Mol. Pharmacol. (1994) 46:929-936.
Berridge, et al., Br. J. Pharmacol. (1986) 88:345-354.
Morgan G.T. and Micklethwait F.M.G., Journal of the Chemical Society, vol. 89, 1906 pp. 1289-1300 "The Action of Nitrous Acid on the Aryl-sulphonylmetadiamines".
Blazak Z. Chem. Listy, vol. 42, No. 121, 1948, pp. 155-161, "Meziprodukty pro vyrobu barviv".
Brown S.M. et al, Journal of the Chemical Society No. 1, 1950, p. 1019, "p-Cymene-2-sulphonamides".
G.J. Atwell et al, Journal of Medicinal Chemistry, vol. 15, No. 6, Jun. 1972, pp. 611-615, "Potential Antitumor Agents. 12. 9-Anilinoacridines".
Hall C.M. et al, Journal of Medicinal Chemistry, vol. 17, No. 7, Jul. 1974, pp. 685-690, "Quinoline Derivatives as Antiallergy Agents".
Denny W.A. et al, Journal of Medicinal Chemistry, vol. 25, No. 3, Mar. 1982, pp. 276-315, Potential Antitumor Agents. 26. Quantitative Relationships between Experimental Antitumor Activity, Toxicity, and Structure for the General Class of 9-Anilinoacridine Antitumor Agents.
Mekelburger H.-B. et al, Chemische Berichte, vol. 126, No. 5, 1993, pp. 1161-1169, "Repetitive Synthesis of Bulky Dendrimers--A Reversibly Photoactive Dendrimer with Six Azobenzene Side Chains".
Takeuchi Y. et al, Chemical & Pharmaceutical Bulletin, vol. 45, No. 2, Feb. 1997, pp. 406-411, "Synthesis and Antitumor Activity of Fused Quinoline Derivatives. IV. Novel 11-Aminoiindolo[3,2-b]quinolines".
Blade Pique J., Chemical Abstracts, vol. 67, No. 9, Aug. 28, 1967, No. 43813t, p. 4122, "Imidazole Derivatives".
Chemical Abstracts, vol. 69., No. 13, Sep. 23, 1968, No. 52140q, p. 4873, "6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-aniline".
Cournoyer Richard Leo
Keitz Paul Francis
O'Yang Counde
Yasuda Dennis Mitsugu
Clark Janet Pauline
F. Hoffman La Roche AG
Geist Gary
Kaku Janet K.
Sackey Ebenezer
LandOfFree
2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole deriva does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole deriva, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole deriva will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1594198